NIH Awards $1.8M to Pain Therapeutics for Work Toward a Diagnostic Blood Test for Alzheimer’s

NIH Awards $1.8M to Pain Therapeutics for Work Toward a Diagnostic Blood Test for Alzheimer’s
Pain Therapeutics has received a $1.8 million research grant from the National Institutes of Health (NIH) to support the development of a technology to diagnose Alzheimer’s disease (AD) in early stages based on a simple blood test. AD is a progressive disorder, meaning it slowly destroys memory and cognitive skills. This damage is known to start a decade or more before problems appear, and during this early stage people seem to be symptom-free although toxic events are taking place in the brain. Currently, Alzheimer's can’t be detected until symptoms are evident. But if these disease-causing events could be traced, the disease might be diagnosed much earlier than it is now and treatment initiated, potentially slowing its progression and delaying symptom onset. “Finding a way to diagnose disease at an early-stage is vitally important,” Remi Barbier, president and chief executive officer of Pain Therapeutics, said in a press release. “A blood test may help detect Alzheimer’s disease before symptoms occur, or rule out other possible causes of memory problems, or might be used as a biomarker to measure the efficacy of drug candidates during clinical trials.” The potential diagnostic blood-test builds on Pain Therapeutics’ PTI-125, a clinical-stage drug candidate for Alzheimer's. The investigational therapy's underlying science has been publishe
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *